Drug discovery

Global Virtual Clinical Trials Market Report 2020-2027: Players are Strategizing on Developing New Virtual Clinical Trial Technology to Cope with the Augmenting Healthcare Industry - ResearchAndMarkets.com

Wednesday, February 24, 2021 - 12:37pm

The "Virtual Clinical Trials Market Share, Size, Trends, Industry Analysis Report, By Design; By Indication; By Phases; By Regions; Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Virtual Clinical Trials Market Share, Size, Trends, Industry Analysis Report, By Design; By Indication; By Phases; By Regions; Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The growth of virtual clinical trials is mainly owing to the advantages offered by these trials in place of traditional clinical trials.
  • Additionally, COVID-19 pandemic has led to upsurge virtual clinical trials given the trials need to be conducted digitally.
  • Players in the market are strategizing on developing new virtual clinical trial technology to cope up with the augmenting healthcare industry and thereby, establish their market place.

Mispro Expanding Technical Services for Clients in its Vivarium Network

Wednesday, February 24, 2021 - 12:49pm

Mispro Biotech Services , a CVO (Contract Vivarium Organization) with locations in all major U.S. biotech clusters, today announced the expansion of Technical Services to their core preclinical research services.

Key Points: 
  • Mispro Biotech Services , a CVO (Contract Vivarium Organization) with locations in all major U.S. biotech clusters, today announced the expansion of Technical Services to their core preclinical research services.
  • Services will include both training and assistance for basic biomethodology, surgical procedure support, and breeding colony management for in vivo studies.
  • Mispro's core preclinical services for clients in their vivarium network include veterinary care, animal husbandry, and regulatory compliance oversight.
  • Mispro Tech Services are currently available at Mispros South San Francisco location and will be rolled out to Mispro's full vivarium network in 2021.

Global $16.9 Billion Hormonal Replacement Therapy (HRT) Drugs Markets, 2015-2019, 2019-2023F, 2025F, 2030F

Wednesday, February 24, 2021 - 11:30am

Increasing occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder growth of drugs for hormonal replacement therapy market.

Key Points: 
  • Increasing occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder growth of drugs for hormonal replacement therapy market.
  • Global Drugs For Hormonal Replacement Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
    4.2.
  • Global Drugs For Hormonal Replacement Therapy Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
    4.3.
  • Global Drugs For Hormonal Replacement Therapy Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase 2 Human Clinical Trial

Wednesday, February 24, 2021 - 8:01am

Vancouver, British Columbia--(Newsfile Corp. - February 24, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FFE: 6UF) ("NeonMind"), announces that it has purchased an initial order of GMP grade psilocybin from Psygen Labs Inc. ("Psygen") for its planned phase 2 human clinical trial expected to begin in Canada later this year.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - February 24, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FFE: 6UF) ("NeonMind"), announces that it has purchased an initial order of GMP grade psilocybin from Psygen Labs Inc. ("Psygen") for its planned phase 2 human clinical trial expected to begin in Canada later this year.
  • Last year NeonMind received supply under the agreement of non-GMP synthetic psilocybin for its preclinical trial which commenced last November.
  • Now, with promising initial results from its preclinical trial, NeonMind has purchased the GMP grade synthetic psilocybin so it can move forward with an application to Health Canada for a phase 2 human clinical trial.
  • The GMP grade synthetic psilocybin was manufactured through Psygen's collaboration with Applied Pharmaceutical Innovation ("API") and a licensed dealer at the University of Alberta.

EQS-News: Relief Reports: NeuroRx Announced that RLF-100(TM) has Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure among Patients with Severe Covid-19 Treated with HFNO at 28 Day Interim Endpoint

Wednesday, February 24, 2021 - 7:01am

NeuroRx is solely responsible for clinical development and regulatory submissions related to RLF-100(TM) in the U.S.

Key Points: 
  • NeuroRx is solely responsible for clinical development and regulatory submissions related to RLF-100(TM) in the U.S.
  • Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications.
  • Its lead drug candidate RLF-100TM (aviptadil) is being investigated in two placebo-controlled U.S. late-stage clinical trials in respiratory deficiency due to COVID-19.
  • Relief holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM.

Altasciences Performs Phase I Studies for FDA Approval of Vibegron

Tuesday, February 23, 2021 - 4:52pm

Altasciences is pleased to have contributed to the recent FDA approval of Vibegron, by performing three early phase clinical trials.

Key Points: 
  • Altasciences is pleased to have contributed to the recent FDA approval of Vibegron, by performing three early phase clinical trials.
  • We take tremendous pride in contributing to the FDA approval of much-needed medicines that improve the health and wellbeing of patients, said Amy Denvir, General Manager at Altasciences Kansas clinical pharmacology unit.
  • Altasciences expert clinical teams provided clinical support for two drug-drug interaction studies and a bioavailability trial, conducted in 2018 and 2019, in healthy subjects.
  • These trials were supported by Altasciences data services team, who performed the full data management and reporting for the associated clinical studies.

Global Orphan Drugs Market Research and Outlook 2020-2028: Trends, Growth Opportunities and Forecasts - ResearchAndMarkets.com

Tuesday, February 23, 2021 - 2:42pm

The "Orphan Drugs Market Research and Outlook, 2020 - Trends, Growth Opportunities and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Orphan Drugs Market Research and Outlook, 2020 - Trends, Growth Opportunities and Forecasts to 2028" report has been added to ResearchAndMarkets.com's offering.
  • Orphan Drugs market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Orphan Drugs market types and applications.
  • It is a focused study on Orphan Drugs market space including global and regional eight-year forecasts for revenues as well as proffers detailed snapshots of country-wide Orphan Drugs market revenues.
  • The Orphan Drugs market report presents key trends and dynamics making an impact on the Orphan Drugs companies across the Americas, Europe, Asia Pacific, and Other markets and provides innovative approaches to stay ahead of the competition in the opportunity-rich Orphan Drugs market.

BioPhotas Inc. Grows Global Reach

Tuesday, February 23, 2021 - 1:39pm

ANAHEIM, Calif., Feb. 23, 2021 /PRNewswire/ --BioPhotas, Inc., the global market leader in therapeutic LED Light Therapy devices announced four new aesthetic industry awards for its continued focus on product innovation.

Key Points: 
  • ANAHEIM, Calif., Feb. 23, 2021 /PRNewswire/ --BioPhotas, Inc., the global market leader in therapeutic LED Light Therapy devices announced four new aesthetic industry awards for its continued focus on product innovation.
  • In addition, the Company expanded its global footprint with new additions to its international distribution network.
  • Commenting on the expansion, Mr. Johnson continued, "Despite the devastating global impact of COVID-19, we've been successful in expanding our global reach, particularly in the EU.
  • BioPhotas develops and markets devices for healthcare providers and consumers that conveniently treat a variety of skin, muscle and joint conditions.

Simulations Plus and the University of Pittsburgh Drug Discovery Institute Receive SBIR Grant Funding for Large Molecule Safety Collaboration

Tuesday, February 23, 2021 - 1:30pm

DSS coordinates the DILI-sim Initiative, which is a public-private partnership that has guided development of the DILIsym software package.

Key Points: 
  • DSS coordinates the DILI-sim Initiative, which is a public-private partnership that has guided development of the DILIsym software package.
  • The focus on large molecule safety in an integrated fashion represents an important new direction for both organizations, allowing them to support development of safer large molecule therapeutics.
  • This collaboration will allow DSS to remain at the forefront of drug safety prediction innovation and expand our product offerings.
  • Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions.

RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.

Tuesday, February 23, 2021 - 12:03pm

Expansion of the global Phase 2/3 study to the U.S. will entail adjustments to the protocol based on the FDA's recommendations and ongoing discussions.

Key Points: 
  • Expansion of the global Phase 2/3 study to the U.S. will entail adjustments to the protocol based on the FDA's recommendations and ongoing discussions.
  • The global Phase 2/3 study recently underwent a positive DSMB futility review, which is suggestive that the study has the potential for a positive outcome.
  • The Phase 2 data also showed no material safety differences between the opaganib and placebo treatment arms - further adding to the growing safety database for opaganib.
  • Phase 2 trial evaluating opaganib, the timing of potential emergency use applications for opaganib and the timing of reporting of top-line data for the global Phase 2/3 study with opaganib.